Evaluation of the Prognostic Impact of Decreased Serum beta2 Microglobulin in the First Year of Follow-up of Myeloproliferative Neoplasia (PRODIGE)
Active, not recruitingOBSERVATIONAL
Enrollment
50
Participants
Timeline
Start Date
August 12, 2024
Primary Completion Date
May 31, 2026
Study Completion Date
May 31, 2026
Conditions
Myeloproliferative Neoplasm
Trial Locations (1)
29609
Chu Brest, Brest
All Listed Sponsors
lead
University Hospital, Brest
OTHER
NCT06553638 - Evaluation of the Prognostic Impact of Decreased Serum beta2 Microglobulin in the First Year of Follow-up of Myeloproliferative Neoplasia (PRODIGE) | Biotech Hunter | Biotech Hunter